MEK114375 Study to provide continued access to GSK1120212 treatment

• Research type

  Research Study

• Full title

  MEK114375: A Rollover Study to Provide Continued Treatment with GSK1120212 to Subjects with Solid Tumors and Leukemia

• IRAS ID

  99580

• Contact name

  Paul Nathan

• Sponsor organisation

  GlaxoSmithKline Pharma UK

• Eudract number

  2010-023015-33

• Research summary

  The objective of this study is to provide continued treatment with GSK1120212 (trametinib) for subjects who have previously participated in a study of GSK1120212 but which is being closed. To participate, patients must be currently receiving clinical benefit from taking GSK1120212 and not be showing any signs or symptoms related to taking GSK1120212 that might give rise to concern about their safety.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  13/NW/0028

• Date of REC Opinion

  17 Jan 2013

• REC opinion

  Favourable Opinion